BG Medicine, Inc.

$0.00+0.00%(+$0.00)
TickerSpark Score
65/100
Solid
100
Valuation
60
Profitability
55
Growth
80
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BGMD research report →

52-Week Range50% of range
Low $0.00
Current $0.00
High $0.00

Companywww.bg-medicine.com

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.

CEO
Stephen Hall
IPO
2011
Employees
5
HQ
Waltham, MA, US

Price Chart

+0.00% · this period
$0.00$0.00$0.00May 19Nov 17May 19

Valuation

Market Cap
$1.14K
P/E
-0.00
P/S
0.00
P/B
-0.00
EV/EBITDA
0.30
Div Yield
0.00%

Profitability

Gross Margin
67.75%
Op Margin
-295.66%
Net Margin
-338.63%
ROE
747.43%
ROIC
-485.83%

Growth & Income

Revenue
$1.57M · -43.81%
Net Income
$-5,303,000 · 34.24%
EPS
$-0.55 · 44.44%
Op Income
$-4,630,000
FCF YoY
55.10%

Performance & Tape

52W High
$0.00
52W Low
$0.00
50D MA
$0.00
200D MA
$0.00
Beta
-44.60
Avg Volume
1.41K

Get TickerSpark's AI analysis on BGMD

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Feb 4, 16LUBER JEFFREY Rother10,000
Feb 4, 16LUBER JEFFREY Rother0
Dec 9, 15AFEYAN NOUBARsell2,508
Nov 18, 15PAPADOPOULOS STELIOSother5,000
Nov 18, 15AFEYAN NOUBARother5,000
Jul 27, 15AFEYAN NOUBARother508
Jul 27, 15AFEYAN NOUBARsell32
Jul 27, 15AFEYAN NOUBARother254
Jul 27, 15AFEYAN NOUBARsell16
Jul 27, 15AFEYAN NOUBARother254

Our BGMD Coverage

We haven't published any research on BGMD yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate BGMD Report →

Similar Companies